of readily available aminoacids, which is not only an oxygen nucleophile but also a nitrogen nucleophile, in palladium-catalyzed allylic substitution is realized under mild conditions. The chemoselectivity and multiple allylation are controlled by adjusting the reaction conditions. This represents the first example of this convenient access to valuable N,O-diallylated aminoacids. Under the title conditions
Amino lactam sulfonamides as inhibitors of A-beta protein production
申请人:——
公开号:US20030130251A1
公开(公告)日:2003-07-10
This invention relates to novel lactams having the Formula (I):
1
to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.
AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
申请人:Bristol-Myers Squibb Pharma Company
公开号:EP1218377A1
公开(公告)日:2002-07-03
US6503901B1
申请人:——
公开号:US6503901B1
公开(公告)日:2003-01-07
[EN] AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A beta PROTEIN PRODUCTION<br/>[FR] AMINO SULFONAMIDES DE LACTAME UTILISES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A beta
申请人:DU PONT PHARM CO
公开号:WO2001027091A1
公开(公告)日:2001-04-19
This invention relates to novel lactams having Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.